Psychemedics (PMD) 18.48 $PMD
Psychemedics Up 24.6% Since SmarTrend Uptrend Call (PMD)
Comtex SmarTrend(R) - Thu Jul 28, 1:38PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on July 8th, 2016 at $14.46. In approximately 3 weeks, Psychemedics has returned 24.55% as of today's recent price of $18.01.
PMD: 18.48 (-0.05)
Psychemedics Corporation Announces Record Revenues And Earnings
PR Newswire - Tue Jul 26, 3:30PM CDT
Psychemedics Corporation (NASDAQ: PMD) today announced second quarter financial results for the period ended June 30, 2016. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of August 5, 2016 to be paid on August 15, 2016. This will be the Company's 80th consecutive quarterly dividend.
PMD: 18.48 (-0.05)
Shares of PMD Up 27.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue May 17, 12:49AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on February 1st, 2016 at $10.20. In approximately 4 months, Psychemedics has returned 27.45% as of today's recent price of $13.00.
PMD: 18.48 (-0.05)
Psychemedics Up 37.0% Since SmarTrend Uptrend Call (PMD)
Comtex SmarTrend(R) - Mon May 09, 1:18PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on February 1st, 2016 at $10.20. In approximately 3 months, Psychemedics has returned 36.96% as of today's recent price of $13.97.
PMD: 18.48 (-0.05)
Shares of PMD Up 39.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Apr 29, 1:02PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on February 1st, 2016 at $10.20. In approximately 3 months, Psychemedics has returned 39.80% as of today's recent price of $14.26.
PMD: 18.48 (-0.05)
Psychemedics posts 1Q loss
Automated Insights - Tue Apr 26, 5:21PM CDT
ACTON, Mass. (AP) _ Psychemedics Corp. (PMD) on Tuesday reported a first-quarter loss of $23,000, after reporting a profit in the same period a year earlier.
PMD: 18.48 (-0.05)
Psychemedics Corporation Announces Quarterly Results
PR Newswire - Tue Apr 26, 4:45PM CDT
Psychemedics Corporation (NASDAQ: PMD) today announced first quarter financial results for the period ended March 31, 2016. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of May 6, 2016 to be paid on May 18, 2016. This will be the Company's 79th consecutive quarterly dividend.
PMD: 18.48 (-0.05)
Shares of PMD Up 43.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Apr 21, 12:55AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on February 1st, 2016 at $10.20. In approximately 3 months, Psychemedics has returned 43.09% as of today's recent price of $14.60.
PMD: 18.48 (-0.05)
Psychemedics Has Returned 37.7% Since SmarTrend Recommendation (PMD)
Comtex SmarTrend(R) - Wed Apr 13, 1:30PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on February 1st, 2016 at $10.20. In approximately 2 months, Psychemedics has returned 37.75% as of today's recent price of $14.05.
PMD: 18.48 (-0.05)
Psychemedics Has Returned 26.1% Since SmarTrend Recommendation (PMD)
Comtex SmarTrend(R) - Tue Mar 29, 1:47PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on February 1st, 2016 at $10.20. In approximately 2 months, Psychemedics has returned 26.08% as of today's recent price of $12.86.
PMD: 18.48 (-0.05)
Psychemedics posts 4Q profit
Automated Insights - Wed Feb 10, 5:25PM CST
ACTON, Mass. (AP) _ Psychemedics Corp. (PMD) on Wednesday reported fourth-quarter net income of $185,000.
PMD: 18.48 (-0.05)
Psychemedics Corporation Announces Quarterly And Annual Results
PR Newswire - Wed Feb 10, 4:20PM CST
Psychemedics Corporation (NASDAQ MD) today announced fourth quarter and year-end financial results for the period ended December 31, 2015. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of February 22, 2016 to be paid on March 4, 2016. This will be the Company's 78th consecutive quarterly dividend.
PMD: 18.48 (-0.05)
BUYINS.NET: PMD SqueezeTrigger Price is $10.29. There is $378,290 That Short Sellers Still Need To Cover.
M2 - Tue Feb 09, 10:22AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring PetroMagdalena Energy Corp (NASDAQ MD) in real time and just received an alert that PMD is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 36200 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $10.29. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
PMD: 18.48 (-0.05)
Shares of PMD Down 21.5% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Jan 28, 10:47AM CST
SmarTrend identified a Downtrend for Psychemedics (NASDAQ MD) on December 29th, 2015 at $10.20. In approximately 1 month, Psychemedics has returned 21.53% as of today's recent price of $8.00.
PMD: 18.48 (-0.05)
North America Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019
M2 - Tue Jan 26, 4:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/5jg3ps/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019 - North America Version " report to their offering. A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenomics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Clinical Laboratory, Molecular Diagnostic and Genomic Testing Services - 2016 to 2019 North America Version" Features - Data that analysts and planners can use - Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing - Make facilities planning decisions - Forecast demand for new testing regimes or technologies - Make research investment decisions Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Market Sizes - North America 6. The Future of the Clinical Laboratory Companies Mentioned - Acibadem Labmed Laboratory - ACM Medical Laboratory - Adicon Clinical Laboratories, Inc. - Alere Inc - American Pathology Partners, Inc. - ARUP Laboratories, Inc. - Ascend Clinical, LLC - Aurora Diagnostics, LLC - Biomnis (France) - Bio-Reference Laboratories, Inc. - Bioscientia Institut fuer Medizinische Diagnostik GmbH - BP Lab - Caris Life Sciences, Inc. - Centrex Clinical Laboratories, Inc. - Clarient, Inc. - Clongen Laboratories LLC - CompuNet Clinical Laboratories, LLC - Diagn?sticos da Am?rica (DASA) - DL Reference Laboratory - Enzo Biochem, Inc. - Exagen Diagnostics, Inc. - Genomic Health, Inc. - Genzyme Corporation - Gribbles Pathology - Integrated Regional Laboratories, Inc. - Predictive Biosciences, Inc. - Psychemedics Corp. - Rosetta Genomics Inc. - Signal Genetics LLC - Solstas Lab Partners - Sonic Healthcare Limited - Spectra Spectra Laboratories, Inc. - The Doctor's Laboratory (Sonic Healthcare U.K.) - Unilabs SA - Vira Cor-Ibt Laboratories For more information visit http://www.researchandmarkets.com/research/5jg3ps/clinical
PMD: 18.48 (-0.05), BRLI: 34.69 (+0.08), ALR: 37.50 (+0.94), ARDX: 10.68 (+0.06), GHDX: 29.03 (+0.30), ENZ: 6.97 (+0.27)
Latin America, Africa & Middle East Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market 2016 to 2019
M2 - Mon Jan 25, 3:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/nlg4t5/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019 - Latin America, Africa & Middle East" report to their offering. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. Report Highlights - Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing - Make facilities planning decisions - Forecast demand for new testing regimes or technologies - Make research investment decisions - Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand - Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges - Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth - Again, assistance in using the information is normally provided without additional charges Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 2.5 National and Regional Diversity 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Markets - Latin America, Africa & The Middle East 6. The Future of the Clinical Laboratory Key Companies - Quest Diagnostics - Laboratory Corporation of America - Lifelabs Medical Laboratory Services - Genzyme Corporation - Sonic Healthcare Limited - Exagen Diagnostics, Inc. - Clongen Laboratories LLC - Clinical Reference Laboratory, Inc. - Rosetta Genomics Inc. - Mid America Clinical Laboratories, LLC - Alere Inc - Caris Life Sciences, Inc. - Psychemedics Corp. - Aurora Diagnostics, LLC - DL Reference Laboratory - Myriad Genetics, Inc. - Pathology Inc. - Gribbles Pathology - BP Lab - Adicon Clinical Laboratories, Inc. - Diagn?sticos da Am?rica (DASA) - Medicus Phillipines Inc. - Kingmed Diagnostics - Ascend Clinical, LLC - Unilabs SA - American Pathology Partners, Inc. - Centrex Clinical Laboratories, Inc. - Integrated Regional Laboratories, Inc. - Vira Cor-Ibt Laboratories - Clarient, Inc. - Genomic Health, Inc. - ARUP Laboratories, Inc. - MEDTOX Scientific, Inc. - Solstas Lab Partners - Predictive Biosciences, Inc. For more information visit http://www.researchandmarkets.com/research/nlg4t5/clinical
PMD: 18.48 (-0.05), MYGN: 30.98 (-1.09), ALR: 37.50 (+0.94), ARDX: 10.68 (+0.06), GHDX: 29.03 (+0.30), DGX: 86.36 (+1.05)
Europe Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019
M2 - Fri Jan 22, 9:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/qbs9gc/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019 - Europe Version" report to their offering. A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. Make investment decisions and valuations with confidence using the latest data. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 6. Country Markets - Europe 7. The Future of the Clinical Laboratory Companies Mentioned - Quest Diagnostics - Laboratory Corporation of America - Lifelabs Medical Laboratory Services - ACM Medical Laboratory - Spectra Spectra Laboratories, Inc. - Bio-Reference Laboratories, Inc. - Signal Genetics LLC - CompuNet Clinical Laboratories, LLC - Genzyme Corporation - Sonic Healthcare Limited - Exagen Diagnostics, Inc. - Clongen Laboratories LLC - Clinical Reference Laboratory, Inc. - Rosetta Genomics Inc. - Psychemedics Corp. - Aurora Diagnostics, LLC - DL Reference Laboratory - Myriad Genetics, Inc. - Bioscientia Institut fuer Medizinische Diagnostik GmbH - Acibadem Labmed Laboratory - Claymon Biomnis Laboratories Ltd. - Biomnis (France) - The Doctor's Laboratory (Sonic Healthcare U.K.) - Unilabs SA - American Pathology Partners, Inc. - Centrex Clinical Laboratories, Inc. - Integrated Regional Laboratories, Inc. - Vira Cor-Ibt Laboratories - Clarient, Inc. - Genomic Health, Inc. - ARUP Laboratories, Inc. - MEDTOX Scientific, Inc. - Solstas Lab Partners - Predictive Biosciences, Inc. - Enzo Biochem, Inc. For more information visit http://www.researchandmarkets.com/research/qbs9gc/clinical
PMD: 18.48 (-0.05), MYGN: 30.98 (-1.09), BRLI: 34.69 (+0.08), ARDX: 10.68 (+0.06), GHDX: 29.03 (+0.30), ENZ: 6.97 (+0.27), DGX: 86.36 (+1.05)
Cannabis Testing Challenges Create Opportunity for DigiPath, Inc. (DIGP)
ACCESSWIRE - Tue Dec 01, 7:02AM CST
SEATTLE. WA / ACCESSWIRE / December 1, 2015 / The cannabis industry could reach $35 billion in size by 2020, according to ArcView Research. However, cannabis continues to be a banned substance under U.S. federal law, while being legal only under state law in 23 states - and on an inconsistent basis. These states have licensed a number of cannabis testing laboratories, but some have struggled to remain compliant with applicable state standards.
PMD: 18.48 (-0.05), ENZ: 6.97 (+0.27), NEO: 8.72 (-0.40)
Cannabis Chemistry: Few Plants Are as Poorly Understood
ACCESSWIRE - Wed Nov 04, 7:32AM CST
SEATTLE, WA / ACCESSWIRE / November 4, 2015 / The legal cannabis industry is expected to reach $11 billion in size by 2019 thanks to ongoing legalization of marijuana on a state level, according to ArcView Market Research. While a number of studies have demonstrated the plant's efficacy in treating medical conditions like cancer pain and childhood epilepsy, researchers are quickly discovering just how little they know about different cannabis strains and their mechanisms of action.
PMD: 18.48 (-0.05)
Psychemedics Up 24.6% Since SmarTrend Uptrend Call (PMD)
Comtex SmarTrend(R) - Thu Jul 28, 1:38PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on July 8th, 2016 at $14.46. In approximately 3 weeks, Psychemedics has returned 24.55% as of today's recent price of $18.01. PMD: 18.48 (-0.05)
Psychemedics Corporation Announces Record Revenues And Earnings
PR Newswire - Tue Jul 26, 3:30PM CDT
Psychemedics Corporation (NASDAQ: PMD) today announced second quarter financial results for the period ended June 30, 2016. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of August 5, 2016 to be paid on August 15, 2016. This will be the Company's 80th consecutive quarterly dividend.
PMD: 18.48 (-0.05)
Shares of PMD Up 27.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue May 17, 12:49AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on February 1st, 2016 at $10.20. In approximately 4 months, Psychemedics has returned 27.45% as of today's recent price of $13.00. PMD: 18.48 (-0.05)
Psychemedics Up 37.0% Since SmarTrend Uptrend Call (PMD)
Comtex SmarTrend(R) - Mon May 09, 1:18PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on February 1st, 2016 at $10.20. In approximately 3 months, Psychemedics has returned 36.96% as of today's recent price of $13.97. PMD: 18.48 (-0.05)
Shares of PMD Up 39.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Apr 29, 1:02PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on February 1st, 2016 at $10.20. In approximately 3 months, Psychemedics has returned 39.80% as of today's recent price of $14.26. PMD: 18.48 (-0.05)
Psychemedics posts 1Q loss
Automated Insights - Tue Apr 26, 5:21PM CDT
ACTON, Mass. (AP) _ Psychemedics Corp. (PMD) on Tuesday reported a first-quarter loss of $23,000, after reporting a profit in the same period a year earlier.
PMD: 18.48 (-0.05)
Psychemedics Corporation Announces Quarterly Results
PR Newswire - Tue Apr 26, 4:45PM CDT
Psychemedics Corporation (NASDAQ: PMD) today announced first quarter financial results for the period ended March 31, 2016. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of May 6, 2016 to be paid on May 18, 2016. This will be the Company's 79th consecutive quarterly dividend.
PMD: 18.48 (-0.05)
Shares of PMD Up 43.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Apr 21, 12:55AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on February 1st, 2016 at $10.20. In approximately 3 months, Psychemedics has returned 43.09% as of today's recent price of $14.60. PMD: 18.48 (-0.05)
Psychemedics Has Returned 37.7% Since SmarTrend Recommendation (PMD)
Comtex SmarTrend(R) - Wed Apr 13, 1:30PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on February 1st, 2016 at $10.20. In approximately 2 months, Psychemedics has returned 37.75% as of today's recent price of $14.05. PMD: 18.48 (-0.05)
Psychemedics Has Returned 26.1% Since SmarTrend Recommendation (PMD)
Comtex SmarTrend(R) - Tue Mar 29, 1:47PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on February 1st, 2016 at $10.20. In approximately 2 months, Psychemedics has returned 26.08% as of today's recent price of $12.86. PMD: 18.48 (-0.05)
Psychemedics posts 4Q profit
Automated Insights - Wed Feb 10, 5:25PM CST
ACTON, Mass. (AP) _ Psychemedics Corp. (PMD) on Wednesday reported fourth-quarter net income of $185,000.
PMD: 18.48 (-0.05)
Psychemedics Corporation Announces Quarterly And Annual Results
PR Newswire - Wed Feb 10, 4:20PM CST
Psychemedics Corporation (NASDAQ
MD) today announced fourth quarter and year-end financial results for the period ended December 31, 2015. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of February 22, 2016 to be paid on March 4, 2016. This will be the Company's 78th consecutive quarterly dividend. PMD: 18.48 (-0.05)
BUYINS.NET: PMD SqueezeTrigger Price is $10.29. There is $378,290 That Short Sellers Still Need To Cover.
M2 - Tue Feb 09, 10:22AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring PetroMagdalena Energy Corp (NASDAQ
MD) in real time and just received an alert that PMD is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 36200 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $10.29. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com . PMD: 18.48 (-0.05)
Shares of PMD Down 21.5% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Jan 28, 10:47AM CST
SmarTrend identified a Downtrend for Psychemedics (NASDAQ
MD) on December 29th, 2015 at $10.20. In approximately 1 month, Psychemedics has returned 21.53% as of today's recent price of $8.00. PMD: 18.48 (-0.05)
North America Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019
M2 - Tue Jan 26, 4:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/5jg3ps/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019 - North America Version " report to their offering. A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenomics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Clinical Laboratory, Molecular Diagnostic and Genomic Testing Services - 2016 to 2019 North America Version" Features - Data that analysts and planners can use - Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing - Make facilities planning decisions - Forecast demand for new testing regimes or technologies - Make research investment decisions Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Market Sizes - North America 6. The Future of the Clinical Laboratory Companies Mentioned - Acibadem Labmed Laboratory - ACM Medical Laboratory - Adicon Clinical Laboratories, Inc. - Alere Inc - American Pathology Partners, Inc. - ARUP Laboratories, Inc. - Ascend Clinical, LLC - Aurora Diagnostics, LLC - Biomnis (France) - Bio-Reference Laboratories, Inc. - Bioscientia Institut fuer Medizinische Diagnostik GmbH - BP Lab - Caris Life Sciences, Inc. - Centrex Clinical Laboratories, Inc. - Clarient, Inc. - Clongen Laboratories LLC - CompuNet Clinical Laboratories, LLC - Diagn?sticos da Am?rica (DASA) - DL Reference Laboratory - Enzo Biochem, Inc. - Exagen Diagnostics, Inc. - Genomic Health, Inc. - Genzyme Corporation - Gribbles Pathology - Integrated Regional Laboratories, Inc. - Predictive Biosciences, Inc. - Psychemedics Corp. - Rosetta Genomics Inc. - Signal Genetics LLC - Solstas Lab Partners - Sonic Healthcare Limited - Spectra Spectra Laboratories, Inc. - The Doctor's Laboratory (Sonic Healthcare U.K.) - Unilabs SA - Vira Cor-Ibt Laboratories For more information visit http://www.researchandmarkets.com/research/5jg3ps/clinical
PMD: 18.48 (-0.05), BRLI: 34.69 (+0.08), ALR: 37.50 (+0.94), ARDX: 10.68 (+0.06), GHDX: 29.03 (+0.30), ENZ: 6.97 (+0.27)
Latin America, Africa & Middle East Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market 2016 to 2019
M2 - Mon Jan 25, 3:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/nlg4t5/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019 - Latin America, Africa & Middle East" report to their offering. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. Report Highlights - Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing - Make facilities planning decisions - Forecast demand for new testing regimes or technologies - Make research investment decisions - Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand - Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges - Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth - Again, assistance in using the information is normally provided without additional charges Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 2.5 National and Regional Diversity 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Markets - Latin America, Africa & The Middle East 6. The Future of the Clinical Laboratory Key Companies - Quest Diagnostics - Laboratory Corporation of America - Lifelabs Medical Laboratory Services - Genzyme Corporation - Sonic Healthcare Limited - Exagen Diagnostics, Inc. - Clongen Laboratories LLC - Clinical Reference Laboratory, Inc. - Rosetta Genomics Inc. - Mid America Clinical Laboratories, LLC - Alere Inc - Caris Life Sciences, Inc. - Psychemedics Corp. - Aurora Diagnostics, LLC - DL Reference Laboratory - Myriad Genetics, Inc. - Pathology Inc. - Gribbles Pathology - BP Lab - Adicon Clinical Laboratories, Inc. - Diagn?sticos da Am?rica (DASA) - Medicus Phillipines Inc. - Kingmed Diagnostics - Ascend Clinical, LLC - Unilabs SA - American Pathology Partners, Inc. - Centrex Clinical Laboratories, Inc. - Integrated Regional Laboratories, Inc. - Vira Cor-Ibt Laboratories - Clarient, Inc. - Genomic Health, Inc. - ARUP Laboratories, Inc. - MEDTOX Scientific, Inc. - Solstas Lab Partners - Predictive Biosciences, Inc. For more information visit http://www.researchandmarkets.com/research/nlg4t5/clinical
PMD: 18.48 (-0.05), MYGN: 30.98 (-1.09), ALR: 37.50 (+0.94), ARDX: 10.68 (+0.06), GHDX: 29.03 (+0.30), DGX: 86.36 (+1.05)
Europe Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019
M2 - Fri Jan 22, 9:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/qbs9gc/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2016 to 2019 - Europe Version" report to their offering. A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. Make investment decisions and valuations with confidence using the latest data. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 6. Country Markets - Europe 7. The Future of the Clinical Laboratory Companies Mentioned - Quest Diagnostics - Laboratory Corporation of America - Lifelabs Medical Laboratory Services - ACM Medical Laboratory - Spectra Spectra Laboratories, Inc. - Bio-Reference Laboratories, Inc. - Signal Genetics LLC - CompuNet Clinical Laboratories, LLC - Genzyme Corporation - Sonic Healthcare Limited - Exagen Diagnostics, Inc. - Clongen Laboratories LLC - Clinical Reference Laboratory, Inc. - Rosetta Genomics Inc. - Psychemedics Corp. - Aurora Diagnostics, LLC - DL Reference Laboratory - Myriad Genetics, Inc. - Bioscientia Institut fuer Medizinische Diagnostik GmbH - Acibadem Labmed Laboratory - Claymon Biomnis Laboratories Ltd. - Biomnis (France) - The Doctor's Laboratory (Sonic Healthcare U.K.) - Unilabs SA - American Pathology Partners, Inc. - Centrex Clinical Laboratories, Inc. - Integrated Regional Laboratories, Inc. - Vira Cor-Ibt Laboratories - Clarient, Inc. - Genomic Health, Inc. - ARUP Laboratories, Inc. - MEDTOX Scientific, Inc. - Solstas Lab Partners - Predictive Biosciences, Inc. - Enzo Biochem, Inc. For more information visit http://www.researchandmarkets.com/research/qbs9gc/clinical
PMD: 18.48 (-0.05), MYGN: 30.98 (-1.09), BRLI: 34.69 (+0.08), ARDX: 10.68 (+0.06), GHDX: 29.03 (+0.30), ENZ: 6.97 (+0.27), DGX: 86.36 (+1.05)
Cannabis Testing Challenges Create Opportunity for DigiPath, Inc. (DIGP)
ACCESSWIRE - Tue Dec 01, 7:02AM CST
SEATTLE. WA / ACCESSWIRE / December 1, 2015 / The cannabis industry could reach $35 billion in size by 2020, according to ArcView Research. However, cannabis continues to be a banned substance under U.S. federal law, while being legal only under state law in 23 states - and on an inconsistent basis. These states have licensed a number of cannabis testing laboratories, but some have struggled to remain compliant with applicable state standards.
PMD: 18.48 (-0.05), ENZ: 6.97 (+0.27), NEO: 8.72 (-0.40)
Cannabis Chemistry: Few Plants Are as Poorly Understood
ACCESSWIRE - Wed Nov 04, 7:32AM CST
SEATTLE, WA / ACCESSWIRE / November 4, 2015 / The legal cannabis industry is expected to reach $11 billion in size by 2019 thanks to ongoing legalization of marijuana on a state level, according to ArcView Market Research. While a number of studies have demonstrated the plant's efficacy in treating medical conditions like cancer pain and childhood epilepsy, researchers are quickly discovering just how little they know about different cannabis strains and their mechanisms of action.
PMD: 18.48 (-0.05)
